RxDoctor Payments Data

Jeffrey Abrams, MD

Gastroenterology · Phila, PANPI 1174582076

Payments from drug & device makers

$2,154in general payments, 2019–2025

Across 83 payments — averaging $25.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$687
  • Depuy Synthes Products, Inc.$585
  • Heartflow, Inc.$204
  • Takeda Pharmaceuticals U.S.A., Inc.$183
  • Bristol Myers Squibb$149
  • Laborie Medical Technologies Corp.$65
  • plus $281 from 10 others

What the payments were for

  • Consulting fees$58527%
  • Speaking & faculty fees$1507%
  • Food & beverage$1,41966%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,154 in reported general payments places this provider in the 45th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$208,898
Medicare patients
639
Services billed
3,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntyvioVedolizumab12$103,919
CreonLipase/Protease/Amylase21$80,716
LinzessLinaclotide52$67,086
IbsrelaTenapanor Hcl26$62,642
XifaxanRifaximin18$47,633
Mesalamine35$18,894
Dexlansoprazole DrDexlansoprazole28$16,848
Octreotide Acetate11$5,900
Pantoprazole Sodium270$4,320
Balsalazide Disodium17$3,838
Omeprazole219$3,387
Famotidine149$3,129
Colestipol Hcl45$2,311
Lubiprostone11$2,216
Esomeprazole Magnesium61$1,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$687$147,80273 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$183$103,91912 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$15$47,63318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Phila

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →